MD Anderson and EMD Serono enter 3-year strategic collaboration to accelerate development of investigational oncology/immuno-oncology compounds

(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced a three-year strategic collaboration, with the aim of more quickly advancing the development of investigational cancer therapies in four cancers -- breast, colorectal, glioblastoma and leukemia.